|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goss PE, Strasser-Weippl K, Lee-Bychkovsky
BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE, Pramesh CS,
Badovinac-Crnjevic T, Sheikine Y, et al: Challenges to effective
cancer control in China, India and Russia. Lancet Oncol.
15:489–538. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Varghese C and Shin HR: Strengthening
cancer control in China. Lancet Oncol. 15:484–485. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adam R: Chemotherapy and surgery: New
perspectives on the treatment of unresectable liver metastases. Ann
Oncol. 14 Suppl 2:ii13–ii16. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salah S, Ardissone F, Gonzalez M, Gervaz
P, Riquet M, Watanabe K, Zabaleta J, Al-Rimawi D, Toubasi S, Massad
E, et al: Pulmonary metastasectomy in colorectal cancer patients
with previously resected liver metastasis: Pooled analysis. Ann
Surg Oncol. 22:1844–1850. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van den Eynde M and Hendlisz A: Treatment
of colorectal liver metastases: A review. Rev Recent Clin Trials.
4:56–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maffione AM, Lopci E, Bluemel C,
Giammarile F, Herrmann K and Rubello D: Diagnostic accuracy and
impact on management of (18)F-FDG PET and PET/CT in colorectal
liver metastasis: A meta-analysis and systematic review. Eur J Nucl
Med Mol Imaging. 42:152–163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tomlinson JS, Jarnagin WR, DeMatteo RP,
Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH and
D'Angelica M: Actual 10-year survival after resection of colorectal
liver metastases defines cure. J Clin Oncol. 25:4575–4580. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fong Y, Fortner J, Sun RL, Brennan MF and
Blumgart LH: Clinical score for predicting recurrence after hepatic
resection for metastatic colorectal cancer: Analysis of 1001
consecutive cases. Ann Surg. 230:309–321. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
House MG, Kemeny NE, Gonen M, Fong Y,
Allen PJ, Paty PB, DeMatteo RP, Blumgart LH, Jarnagin WR and
D'Angelica MI: Comparison of adjuvant systemic chemotherapy with or
without hepatic arterial infusional chemotherapy after hepatic
resection for metastatic colorectal cancer. Ann Surg. 254:851–856.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kobuchi S, Ito Y, Hayakawa T, Nishimura A,
Shibata N, Takada K and Sakaeda T: Pharmacokinetic-pharmacodynamic
(PK-PD) modeling and simulation of 5-fluorouracil for erythropenia
in rats. J Pharmacol Toxicol Methods. 70:134–144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu X, Tao L, Cai R, Prigge J and Zhang X:
A mutant type 2 herpes simplex virus deleted for the protein kinase
domain of the ICP10 gene is a potent oncolytic virus. Mol Ther.
13:882–890. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anzivino E, Fioriti D, Mischitelli M,
Bellizzi A, Barucca V, Chiarini F and Pietropaolo V: Herpes simplex
virus infection in pregnancy and in neonate: Status of art of
epidemiology, diagnosis, therapy and prevention. Virol J. 6:402009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao Q, Zhang W, Ning Z, Zhuang X, Lu H,
Liang J, Li J, Zhang Y, Dong Y, Zhang Y, et al: A novel oncolytic
herpes simplex virus type 2 has potent anti-tumor activity. PloS
One. 9:e931032014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li H, Dutuor A, Fu X and Zhang X:
Induction of strong antitumor immunity by an HSV-2-based oncolytic
virus in a murine mammary tumor model. J Gene Med. 9:161–169. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu X, Tao L and Zhang X: An oncolytic
virus derived from type 2 herpes simplex virus has potent
therapeutic effect against metastatic ovarian cancer. Cancer Gene
Ther. 14:480–487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Workenhe ST, Simmons G, Pol JG, Lichty BD,
Halford WP and Mossman KL: Immunogenic HSV-mediated oncolysis
shapes the antitumor immune response and contributes to therapeutic
efficacy. Mol Ther. 22:123–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bollino D, Colunga A, Li B and Aurelian L:
ΔPK oncolytic activity includes modulation of the tumor cell
milieu. J Gen Virol. 97:496–508. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Colunga AG, Laing JM and Aurelian L: The
HSV-2 mutant DeltaPK induces melanoma oncolysis through
nonredundant death programs and associated with autophagy and
pyroptosis proteins. Gene Ther. 17:315–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang H, Peng T, Li J, Wang Y, Zhang W,
Zhang P, Peng S, Du T, Li Y, Yan Q and Liu B: Treatment of colon
cancer with oncolytic herpes simplex virus in preclinical models.
Gene Ther. 23:450–459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kozlowski JM, Fidler IJ, Campbell D, Xu
ZL, Kaighn ME and Hart IR: Metastatic behavior of human tumor cell
lines grown in the nude mouse. Cancer Res. 44:3522–3529.
1984.PubMed/NCBI
|
|
22
|
Yin L, Zhao C, Han J, Li Z, Zhen Y, Xiao
R, Xu Z and Sun Y: Antitumor effects of oncolytic herpes simplex
virus type 2 against colorectal cancer in vitro and in vivo. Ther
Clin Risk Manag. 13:117–130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang H, Peng T, Li J, Wang Y, Zhang W,
Zhang P, Peng S, Du T, Li Y, Yan Q and Liu B: Treatment of colon
cancer with oncolytic herpes simplex virus in preclinical models.
Gene Ther. 23:450–459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fu X, Rivera A, Tao L and Zhang X: An
HSV-2 based oncolytic virus can function as an attractant to guide
migration of adoptively transferred T cells to tumor sites.
Oncotarget. 6:902–914. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Toda M, Rabkin SD, Kojima H and Martuza
RL: Herpes simplex virus as an in situ cancer vaccine for the
induction of specific anti-tumor immunity. Hum Gene Ther.
10:385–393. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ottolino-Perry K, Acuna SA, Angarita FA,
Sellers C, Zerhouni S, Tang N and McCart JA: Oncolytic vaccinia
virus synergizes with irinotecan in colorectal cancer. Mol Oncol.
9:1539–1552. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Esin E and Yalcin S: Maintenance strategy
in metastatic colorectal cancer: A systematic review. Cancer Treat
Rev. 42:82–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Russell SJ, Peng KW and Bell JC: Oncolytic
virotherapy. Nat Biotechnol. 30:658–670. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sze DY, Reid TR and Rose SC: Oncolytic
virotherapy. J Vasc Interv Radiol. 24:1115–1122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pol J, Kroemer G and Galluzzi L: First
oncolytic virus approved for melanoma immunotherapy.
Oncoimmunology. 5:e11156412015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shinozaki K, Ebert O and Woo SL:
Eradication of advanced hepatocellular carcinoma in rats via
repeated hepatic arterial infusions of recombinant VSV. Hepatology.
41:196–203. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fong Y, Kim T, Bhargava A, Schwartz L,
Brown K, Brody L, Covey A, Karrasch M, Getrajdman G, Mescheder A,
et al: A herpes oncolytic virus can be delivered via the
vasculature to produce biologic changes in human colorectal cancer.
Mol Ther. 17:389–394. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Toda M, Rabkin SD, Kojima H and Martuza
RL: Herpes simplex virus as an in situ cancer vaccine for the
induction of specific anti-tumor immunity. Hum Gene Ther.
10:385–393. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi Y, Liu CH, Roberts AI, Das J, Xu G,
Ren G, Zhang Y, Zhang L, Yuan ZR, Tan HS, et al:
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and
T-cell responses: What we do and don't know. Cell Res. 16:126–133.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Croxford AL, Spath S and Becher B: GM-CSF
in neuroinflammation: Licensing myeloid cells for tissue damage.
Trends Immunol. 36:651–662. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cerwenka A, Baron JL and Lanier LL:
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1)
permits natural killer cell-mediated rejection of a MHC class
I-bearing tumor in vivo. Proc Natl Acad Sci USA. 98:11521–11526.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Diefenbach A, Jensen ER, Jamieson AM and
Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate
tumor immunity. Nature. 413:165–171. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density and location of immune cells
within human colorectal tumors predict clinical outcome. Science.
313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pancione M, Giordano G, Remo A, Febbraro
A, Sabatino L, Manfrin E, Ceccarelli M and Colantuoni V: Immune
escape mechanisms in colorectal cancer pathogenesis and liver
metastasis. J Immunol Res. 2014:6868792014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alpizar YA, Chain B, Collins MK, Greenwood
J, Katz D, Stauss HJ and Mitchison NA: Ten years of progress in
vaccination against cancer: The need to counteract cancer evasion
by dual targeting in future therapies. Cancer Immunol Immunother.
60:1127–1135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Seebauer CT, Brunner S, Glockzin G, Piso
P, Ruemmele P, Schlitt HJ, Geissler EK, Fichtner-Feigl S and
Kesselring R: Peritoneal carcinomatosis of colorectal cancer is
characterized by structural and functional reorganization of the
tumor microenvironment inducing senescence and proliferation arrest
in cancer cells. Oncoimmunology. 5:e12425432016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Workenhe ST, Simmons G, Pol JG, Lichty BD,
Halford WP and Mossman KL: Immunogenic HSV-mediated oncolysis
shapes the antitumor immune response and contributes to therapeutic
efficacy. Mol Ther. 22:123–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
